Becton Dickinson (BDX)
NYSE: BDX · Medical Instruments · Franklin Lakes, NJ
Our rating: Positive
Positive reaffirmed at $177.07, moderate conviction, August 6, 2026.
Breaks if: The Positive call breaks if reported free cash flow falls below $3.5B on a trailing twelve-month basis at any point in the next four quarters — that would indicate the amortization-heavy income statement is concealing genuine cash-generation erosion rather than non-cash accounting drag. Separately, two consecutive quarters of revenue growth below 3% would dismantle the top-line momentum pillar and move us toward Neutral; both conditions occurring together would move us toward Cautious.
Key figures
| Market value | $58.0B |
|---|---|
| Revenue, last 12 months | $23.3B |
| Net income, last 12 months | $941M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | 61.6× |
| Free cash flow yield | n/a |
| Dividend yield | 1.9% |
| Operating margin | 10.7% |
| Return on equity | 3.8% |
| Beta to the S&P 500 | 0.39 |
| Volatility, annualized | 26.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| June 30, 2026 | $5.0B | 5.4% | $1.37 | n/a |
| March 31, 2026 | $4.7B | 5.2% | $-1.11 | n/a |
| December 31, 2025 | $5.3B | 1.6% | $1.34 | $549M |
| September 30, 2025 | $8.3B | 52.7% | $1.72 | n/a |
| June 30, 2025 | $4.7B | −5.3% | $2.00 | n/a |
| March 31, 2025 | $4.5B | −11.2% | $1.07 | n/a |
| December 31, 2024 | $5.2B | 9.8% | $1.04 | $588M |
| September 30, 2024 | $5.4B | 6.9% | $1.37 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $9.65B: Claude 8%, Gemini 15%, Mistral 12%
- Diluted earnings per share are at least $1.72: Claude 22%, Gemini 30%, Mistral 18%
7 ledger entries and 46 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.